Given the poor prognosis associated with lung cancer, the ability to diagnose lung cancer in its early stages is considered crucial to achieving decreased lung cancer mortality. Herein, we discuss recent advances in biomarker discovery and evaluation of their potential application in the clinical setting.
Introduction
The dismal 5-year survival rate for patients diagnosed with lung cancer is well known, and currently most patients still have advanced stage lung cancer at diagnosis. The modest improvement experienced in lung cancer treatment within the past few years has mostly been in patients with early disease. It is, therefore, of paramount importance to diagnose and treat cancer at the earliest point, preferably while still in its pre-malignant stage. Recently identified biomarkers have advanced our ability to more accurately predict tumor classification, prognostic/metastatic potential, and response potential to novel chemotherapies. There has been limited success in the discovery of biomarkers for the early detection of lung cancer and pre-malignant lesions. In addition, most of the studies have relied on tissue samples derived from invasive and expensive procedures (such as bronchoscopy) that carry potential risk for the patient. Such biomarkers have not yet been demonstrated to be practical for early detection of lung cancer. A successful biomarker for early detection, like PSA in prostate cancer for example, should be found in specimens obtained from relatively noninvasive procedures, be associated with a high sensitivity and specificity, and be inexpensive to assay. In the current review we discuss recent advances in the identification of potential biomarkers and the development of promising technologies for early detection of lung cancer and pre-malignant lesions.
Biology of lung cancer progression
Increased understanding of the molecular alterations associated with progression from pre-malignancy to invasive lung cancer is helping to identify markers that may indicate biologically significant changes in at-risk populations [1] . Many studies have helped establish a relation between bronchial dysplasia and the increased risk for invasive carcinoma, primarily of the squamous cell type, although larger follow-up studies are required before the natural course of lower grade lesions is fully understood. Also, severe dysplasia and carcinoma-in-situ have been shown to progress to invasive carcinoma in over 50% of cases [2, 3] . Early studies aimed at elucidating a relation between neuroendocrine hyperplasia and invasive neuroendocrine carcinomas are in progress. In 1999, the W.H.O. classified atypical adenomatous hyperplasia (AAH) as a precursor lesion of lung adenocarcinoma. The pre-malignant potential of AAH is less well understood, but with improved identification of small peripheral lesions by methods such as spiral CT, more samples are now becoming available for studies. AAH has been shown to have many of the same molecular alterations as adenocarcinoma, including k-ras mutations, 3p and 9p deletions, aneuploidy, and dysregulation of cell cycle control [4, 5] . Several recent studies have shown AAH to be most closely associated with nonmucinous bronchioloalveolar carcinoma (BAC), although it is not clear whether significant clinical implications are associated with this relation [4, 6-10]. AAH may be smoking related, and is probably an irreversible transformation [5, 11] . Most studies on AAH have been on specimens obtained serendipitously in tissue harvested from patients with a known diagnosis of adenocarcinoma. AAH progression to adenocarcinoma has not been directly demonstrated and it is still unknown at what frequency they transform into invasive cancer.
Biomarker discovery
New high throughput technologies can now simultaneously characterize alterations in expression and structure of thousands of genes and their downstream products. Recently, these methodologies have been used to identify novel biomarkers for early detection of premalignancy and cancer and some of these biomarkers are currently being validated on assays of tumor sets. Comparative genomic hybridization was used to demonstrate frequent amplification of the ␣-catalytic subunit of phosphatidylinositol 3-kinase in non-small cell lung carcinomas (NSCLCs). Subsequent measures of associated kinase activity revealed tumor-specific increases that were most prominent in squamous cell carcinomas [12] . Similarly, cDNA microarray analysis of NSCLCs identified a group of protease inhibitors (eg, maspin) that were overexpressed in comparison to matching normal lung. Validational RT-PCR and immunohistochemical studies confirmed elevated expression of the maspin gene product that was nearly ubiquitous in squamous cell carcinomas [13,14••]. In addition, maspin was found to be expressed in approximately half of bronchial dysplasias and only rarely detected in normal or hyperplastic bronchial tissues [14••] . A cDNA microarray analysis of stage 1A NSCLC has revealed overexpression of three main classes of factors (cytoskeletal, collagens, and metalloproteinases) compared with normal lung [15] . These stage 1A NSCLCs also showed differential expression of 30 genes in comparison to higher stage lung cancer. At the University of Colorado we have used cDNA microarrays to identify overexpression of cancer testis antigens (cTags) in both NSCLCs and small cell lung carcinomas (SCLCs) [16] . Interestingly, in validational mRNA RT-PCR and tissue protein microarray analyses, most of these markers were found to be overexpressed in both NSCLC and SCLC, but some markers were only detected in SCLCs. An evaluation of the expression of these genes in premalignant lesions is currently ongoing. These findings raise the intriguing possibility that markers identified in carcinomas can potentially differentiate which pre-malignant lesions harbor the greatest potential for progression. However, prospective studies will be needed to demonstrate such properties. It will be informative to use high throughput technologies directly on pre-malignant lesions.
Proteomics has recently been introduced to the field of cancer research, and its potential applications are just beginning to be understood. Two approaches are currently in use on lung tissue-MALDI-TOF MS (matrixassisted laser desorption/ionization time of flight mass spectrometry) and SELDI (surface-enhanced laser desorption/ionization). The advantage of proteomics is based on the well-documented phenomena that there may be poor correlation between mRNA expression and protein levels, and proteomics can detect posttranslational modifications not elucidated by nucleic acid studies. Several groups have reported that detection of unique protein peaks can be used to accurately identify pre-malignant (AAH) lesions, tumor classes, and behavioral aspects of tumors such as proclivity to metastasize Proteomic analysis may yield biomarker information with as good or better a degree of practical utility than those being identified by other methodologies. Issues that need to be addressed include the fact that protein peaks do not represent actual proteins and the determination of the specific protein represented in the peak remains difficult and timely. For potential biomarkers identified in all of the above-mentioned high throughput technologies, significant questions remain in respect to their reproducibility and capacity for practical application. Therefore, results from all these technologies must be reproduced in larger validational studies.
Biomarker characterization
A number of recent studies have produced interesting results regarding molecular features associated with progression to malignancy. These studies are based on the well-documented p53-retinoblastoma (Rb) cell-cycle regulatory pathway. Aberrations at multiple locations along this pathway induce loss of control at G1 arrest resulting in unrestrained growth secondary to the absence of apoptosis. Overexpression of p53 has previously been suggested to be associated with a greater risk of progression in bronchial dysplasia [20] , and recent studies have lent support to this contention. A case study, in which multiple dypslasias were followed in two patients, found that lesions in which invasive carcinoma developed showed p53 overexpression and loss of heterozygosity (LOH) at one allele for the FHIT gene whereas these changes were absent in the sites without progression [21] . In a prospective study of 48 former smokers, the expression of a panel of five markers (p53, cyclin D1, cyclin E, Bax, and Bcl2) were characterized by immunohistochemistry in biopsies from sites of dysplastic change and then correlated with subsequent progression to invasive or in situ carcinoma. While neither grade of dysplasia or aberrant expression of any single marker was correlated with progression, aberrant expression of two or more markers was predictive of subsequent progression [22••]. The potential role of angiogenic activity in progression of bronchial lesions has been suggested by the observation of distinct vascular features in some dysplasias termed angiogenic squamous dysplasias (ASDs) [23, 24] . Immunohistochemical demonstration of elevated VEGF expression in association with induction of neuropilin 1 and 2 expression and loss of semaphorin 3F expression has also been recently reported to be associated with the progression of bronchial lesions to highgrade dysplasia and microinvasive carcinoma, although these alterations did not correlate with observed changes of ASD [25•]. Previously the use of these factors involved in the control of cellular proliferation, angiogenesis, and apoptosis as biomarkers has not been enthusiastically embraced because none of them are ubiquitously overexpressed in lung cancers [26] [27] [28] [29] . These recent findings indicate that they may be more reliable markers of early progression than previously thought and also suggest that analyses of multiple markers in the form of a "biomarker panel" could improve overall sensitivity.
Another recent addition to the early detection armamentarium is heterogenous nuclear ribonucleoprotein B1 (hnRNP B1 Sputum cytology screening has historically not been shown to improve the early detection of lung cancer to reduce lung cancer mortality. However, previous studies relied on older technology and poorly constructed cohorts [45,46•,47] . It has been shown that lung cancer, generally centrally located, from high-risk individuals, can be detected by a 3-day pooled collection of sputum prior to roentgenographic appearance [48] [49] [50] . The identification of the most optimal high-risk cohort for screening/early detection has been discussed by Hirsch et al., and is still a subject for investigation [51] . While conventional sputum cytology does not have a sufficiently high level of sensitivity in the general population, it has been shown to be superior to chest radiograph in cases from a preselected cohort.
The future role of sputum examination for early detection of lung cancer and pre-malignancy might include protein and/or nucleic acid analysis. Some have questioned the future for the analysis of free DNA in the sputum [52] , but several studies show promise for genetic analysis on micro-dissected abnormal cells. K-ras and p53 mutations have been detected in the sputum of diagnosed cancer patients [53, 54] . Detection of epigenetic changes in sputum from diagnosed and undiagnosed cancer patients has shown great promise [55] [56] [57] . Aberrant gene methylation of p16 and/or MGMT (06-methyl-guanine DNA methyltransferase) has been detected in the sputum of 100% of squamous cell lung cancer patients and in over 50% of adenocarcinomas [57] [58] [59] . Furthermore, the molecular steps leading to aberrant methylation are being discovered, and include functional variants of NADPH quinone oxireductase and glutathione S-transferases P1 and M1 [58] . In a recent preliminary publication, our group showed a high odds ratio (about 8-fold) for the detection of lung cancer in sputum through demonstration of aberrant methylation in any one gene from an 8-gene panel in individuals with moderate sputum atypia or worse [60] . Proteomics-based sputum analysis may also hold future promise for early detection. A large number of samples suitable for proteomic studies are already available at several institutions.
Breath analysis, presently in its earliest stages of development, is another new technique for biomarker screening that may help in the early detection of roentgenographically occult lung cancer. The concept is that volatile organic compounds (VOCs), mainly alkanes and aromatic compounds, are preferentially produced and ex-haled by lung cancer patients and can be used as accurate markers of malignant disease [61] [62] [63] . Before this method of analysis can be fully appreciated and used issues like expanded study numbers, comparison sideby-side with existing technologies, sensitivity/specificity, and the addition of a pre-malignant cohort need to be addressed.
Conclusion
Significant advances in our understanding of the molecular and genetic machinery of lung cancer development have occurred. However, current research has not yet accomplished the goal of producing an easy, inexpensive, noninvasive, sensitive, and specific biomarker for the early detection of lung cancer and pre-malignancy. The biomarkers that have been identified must be further characterized in respect to their biologic importance and then validated as an early detection assay in larger clinical cohorts. Nevertheless, recent progress in the detection of molecular/genetic changes associated with lung carcinogenesis, in conjunction with improving radiographic technologies, shows great promise for the development of practical lung cancer screening tools in the not too distant future.
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